Beta Bionics Gets FDA Clearance for Mint Pump, Cuts 2026 Guidance

Key Facts

1Beta Bionics received FDA clearance for its Mint patch pump, with a planned launch in the first quarter of 2027.

2The company cut its 2026 revenue guidance due to demand deferral as patients wait for the new product launch.

In a move reflecting a strategic shift toward a multi-product diabetes care platform, Beta Bionics has received FDA clearance for its Mint insulin patch pump. According to reports, the company plans to officially launch the product in the first quarter of 2027. However, the company simultaneously cut its 2026 revenue guidance due to demand deferral, as patients opt to wait for the new technology rather than purchasing current models.

This development comes as financial data reveals transitional pressure, with market anticipation for the upcoming device causing a temporary slowdown in existing sales. Per market data, BBNX stock closed at $22.18 (close September 16, 2026), having traded between a session low of $18.4 and a high of $22.22. These movements reflect a mixed investor response to the long-term bullish milestone of regulatory approval versus short-term revenue headwinds.

Traders should watch for price stability around the $18.4 support level established on September 16, 2026. While the upcoming economic calendar does not list immediate catalysts for the medical device sector, the focus remains on any operational updates regarding production timelines ahead of the scheduled 2027 launch.